hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:25:57 - browse：2817

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

explore

WSS

The stock market has soared this year, but will it last? Experts weigh in

Telehealth startups are trying to fill the menopause care vacuum

Biogen shutters digital health group, ends Apple study, in cost cutting move

Medicare drug price negotiation program allowed for now

Mindstrong's demise and the future of mental health care

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

knowledge

hotspot

explore

Hollywood unions extend contract negotiations for actors

Paxlovid should be available without a positive Covid test

Alkermes shareholders re

A new ‘biological computer' targets cancer while sparing healthy cells

Virginia high school admissions case could be legal follow

Sanders wants to replace patents with prizes for drug inventions

As demand for Covid shots wanes, Moderna seeks its next success

Medicaid, Medicare dual

United colonoscopy coverage change 'may cost lives,' doctors say

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

Medicaid, Medicare dual

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Scientists grapple with ethics of stem cell research

Kaiser Permanente unions announce official strike date

Listen: Who gets the credit for GLP

Dementia risk linked to living in disadvantaged areas: Study

entertainment

explore

focus

explore